A bold marketing move on weight-loss drugs sent HIMS stock soaring, but regulatory and industry backlash is mounting.
- Sagsbehandlingstiden på værgemålsområdet er uholdbar. Det skriver Folketingets Ombudsmand, Henrik Bloch Andersen i en ...
Der bliver arbejdet "på højtryk" i Nyborg Kommune, der i sent i går aftes måtte give omkring 100 borgere besked om at forlade ...
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback